

CHAT, CHECK, CHART

TIPS AND TOOLS: ASSESSMENT AND DOCUMENTATION

CHAT

3 prime questions

Personalized, open-ended questions to gather information on new and refill medication

	NEW MEDICATION	REFILL MEDICATION
PURPOSE	What did your prescriber tell you your medication is for?	This medication has many uses - what do you use it for?
DIRECTION	How did your prescriber tell you to take the medication?	How have you been taking this medication?
MONITORING	What did your prescriber tell you to expect?	How is this medication working? What side effects have you had?

CHECK

4 questions

Evaluate the appropriateness of therapy*



Is therapy **indicated**?



Is therapy **effective**?



Is therapy **safe**?



Is the patient willing to **use/adhere** to therapy?

CHART

Efficient DAP

(eDAP: data, assessment, plan)**

NEW MEDICATION

Scenario: Atorvastatin 40 mg started for 53-year-old male patient, BA, who is a new patient

18/07/2015: Rx 235423

D: LDL 3.5 mmol/L, HDL 0.8 mmol/L, TG 2.0 mmol/L; not diabetic; 30 pack-year smoker; BP 134/89; Current Framingham 10-year CVD risk score >20%; No other medications or medical conditions.

A: Atorvastatin 40 mg indicated for primary hypercholesterolemia. Dose is effective for 35% reduction of baseline CVD risk. No contraindications or reasons for caution. Tx is appropriate.

P: RPh to discuss smoking cessation with patient at next refill in 1 month. BA to monitor for signs of myalgia. -RJP

REFILL MEDICATION

Scenario: Atorvastatin 40 mg started 1 month ago; BA reports no signs of myalgia

15/08/2015: Rx 233783

D: Atorvastatin 40 mg started 1 month ago; BA reports no signs of myalgia.

A: Atorvastatin 40 mg is appropriate; continue statin therapy for reduction of CVD risk. BA tolerating and adherent to therapy.

P: Patient to continue monitoring for myalgia. Consider smoking cessation again at next refill in 3 months. -RJP

*Cipolle R, Strand L, Morley P. *Pharmaceutical Care Practice: The Clinician's Guide*, 2nd ed. New York: McGraw-Hill, 2004.

**Adapted from *Chat, Check, and Chart*, Lisa Guirguis, PhD; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta.